ACP
PDSB icon

Acuta Capital Partners’s PDS Biotechnology PDSB Stock Holding History

Acuta Capital Partners’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-47,195
Closed -$8.84M – 79
2017
Q4 		$8.84M Sell
47,195
-15,475
-25% -$3.11M 1.67% 15
2017
Q3 		$13.4M Sell
62,670
-12,561
-17% -$2.6M 2.41% 10
2017
Q2 		$15.4M Buy
75,231
+7,655
+11% +$1.51M 4.32% 8
2017
Q1 		$12.3M Buy
67,576
+15,563
+30% +$3.08M 2.92% 9
2016
Q4 		$13M Buy
52,013
+16,863
+48% +$3.83M 4.84% 6
2016
Q3 		$7.32M Buy
35,150
+8,650
+33% +$1.71M 2.75% 9
2016
Q2 		$5.36M Buy
26,500
+7,245
+38% +$1.28M 2.57% 12
2016
Q1 		$3.52M Buy
19,255
+11,315
+143% +$2.02M 1.97% 18
2015
Q4 		$1.99M Buy
+7,940
New +$2.56M 0.95% 32

Other funds holding PDSB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acuta Capital Partners's PDSB Position: Q1 2018 in Review

Acuta Capital Partners sold out of PDS Biotechnology (PDSB) in Q1 2018, closing a stake of 47,195 shares — an estimated $8.84M sold.

Acuta Capital Partners first reported a position in PDSB in Q4 2015 and held it in 9 quarters. The position peaked at $15.4M in Q2 2017. 60 funds tracked by Wall St. Rank hold PDSB as of Q1 2018.

  • Acuta Capital Partners reported no remaining PDS Biotechnology position as of Q1 2018 after selling out during the quarter.
  • Acuta Capital Partners sold 47,195 PDS Biotechnology shares in Q1 2018, an estimated $8.84M.
  • Acuta Capital Partners first reported a position in PDS Biotechnology in Q4 2015 and held it in 9 quarters.
  • Acuta Capital Partners's PDS Biotechnology position peaked at $15.4M in Q2 2017.
  • 60 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2018.

Based on Acuta Capital Partners's 13F filing for Q1 2018, filed 15 May 2018.